Synthroid Side Effects: Delayed-Onset Adverse Events You Need to Know

Synthroid is a brand name for levothyroxine sodium, a synthetic form of thyroxine (T4) used to replace or supplement thyroid hormone. It belongs to the same drug class as other levothyroxine products sold under names like Tirosint, Levoxyl, Unithroid, and Euthyrox. It is FDA-approved for hypothyroidism replacement and, at higher intentional doses, for TSH suppression after treatment for certain differentiated thyroid cancers. This article focuses on delayed adverse effects that develop gradually over weeks, months, or years of continued levothyroxine use rather than appearing within the first days of treatment.

The core fact worth remembering: levothyroxine itself does not cause bone loss or heart rhythm problems at a correctly matched dose. The delayed harm comes from a TSH that has quietly drifted below the reference range and stayed there, because thyroid hormone's effects on bone turnover and cardiac conduction accumulate over time rather than appearing acutely. This is why routine follow-up labs, not just symptom-watching, are the primary safeguard for anyone on long-term therapy.

Why these effects show up late instead of right away

Levothyroxine has a long plasma half-life, commonly cited as roughly one week in people with normal thyroid clearance, and it takes about a month or more after any dose change for tissue levels to fully equilibrate. That lag means a dose that is too high will not produce its full effect on the body for several weeks, and slow-building effects like bone remodeling or cardiac strain can take much longer than that to become measurable.

Acute overdose from a single missed or doubled dose is rarely dangerous in an adult without other health problems. The real risk sits in chronic, low-grade over-treatment: a TSH sitting under the lower reference limit for a year or more, often without any symptoms the patient would recognize as a problem. Population-level prescribing data have suggested this pattern is not rare, though exact prevalence figures vary by country, lab reference range, and dataset, and any specific percentage should be checked against current primary literature before being treated as authoritative.

Bone mineral density loss

Excess thyroid hormone speeds up the bone remodeling cycle, and when osteoclast-driven breakdown outpaces osteoblast rebuilding, the result is measurable net bone loss even in people who feel fine. This mechanism is well established in endocrinology; what is less settled is the exact fracture-risk number attached to any specific TSH threshold, because studies vary in cohort, follow-up length, and how "suppressed" is defined.

Large population cohort studies, including Scandinavian data often cited in this area, have linked a chronically suppressed TSH (commonly defined as below roughly 0.5 mIU/L) with a meaningfully higher risk of fracture, particularly at cortical bone sites such as the hip and forearm rather than the spine. Systematic reviews pooling subclinical hyperthyroidism data, whether from endogenous thyroid disease or exogenous over-replacement, have similarly found an elevated hip fracture risk. The direction of the finding is consistent across the literature; the precise relative risk figures in any one study should be verified against the original paper before being quoted to a patient.

Postmenopausal women are the group most consistently flagged as high-risk, because estrogen loss already impairs bone remodeling and TSH suppression compounds it. This is the population most often discussed in guideline language about baseline and follow-up bone density scanning for anyone maintained on a suppressive dose, such as thyroid cancer patients in the years after thyroidectomy. Calcium and vitamin D intake at generally recommended levels may reduce the excess turnover somewhat, but they do not eliminate the risk on their own, dose reduction toward the lowest effective TSH target is the primary lever.

Cardiovascular effects that build over months to years

Subclinical hyperthyroidism from levothyroxine over-replacement increases atrial fibrillation risk in a manner that appears dose- and duration-dependent. Older cohort work, including the well-known Cardiovascular Health Study, found a substantially higher AF incidence in people with a markedly suppressed TSH compared with those in the normal range, with an intermediate risk at only mildly suppressed values. Since these decades-old studies are frequently misquoted online regarding their exact hazard ratios, any specific multiplier cited should be verified against the original publication rather than accepted from secondary sources.

The practical point for a reader on long-term therapy is timing: atrial fibrillation from chronic over-replacement typically does not appear in the first weeks. It tends to surface after one to several years of an undetected TSH drift, which means a person who has been "stable" on the same dose for years is not necessarily safe from this risk if no one has rechecked their labs recently. Systematic reviews of subclinical hyperthyroidism have also reported associations with heart failure and coronary mortality, again with study-to-study variation in exact effect size that a clinician should verify before quoting a number to a patient.

Adrenal crisis: an uncommon but serious unmasking risk

Thyroid hormone increases the rate at which the body clears cortisol. In someone with undiagnosed or borderline adrenal insufficiency, starting levothyroxine can tip an already-marginal cortisol supply into frank insufficiency, sometimes within weeks of the first dose. FDA-approved prescribing information for levothyroxine products carries a warning that initiating thyroid hormone therapy in a patient with concurrent, untreated adrenal insufficiency can precipitate adrenal crisis, this is standard, well-established labeling language rather than a novel or rare-signal finding.

People with symptoms suggestive of adrenal insufficiency before starting levothyroxine, unusual fatigue, skin darkening, low blood pressure on standing, or unexplained low sodium, should have this evaluated before or immediately after starting therapy, since correcting cortisol deficiency generally needs to happen before or alongside thyroid hormone replacement, not after. This is a scenario where self-diagnosis and self-adjustment are not appropriate; it requires a clinician to order and interpret morning cortisol testing.

An emerging related population: checkpoint-inhibitor-associated thyroid dysfunction

A newer and distinct scenario is levothyroxine started after thyroid dysfunction caused by cancer immunotherapy (immune checkpoint inhibitors). These drugs can trigger thyroiditis that swings from a transient hyperthyroid phase into lasting hypothyroidism, at which point levothyroxine replacement is typically needed. A 2025 case report and literature review, and a 2025 best-practices summary on managing checkpoint-inhibitor thyroid dysfunction, describe this pattern and note that management guidance in this specific population is still evolving rather than settled by long-term outcome trials.

• Sintilimab-induced diabetes and thyroid dysfunction, case report and literature review (2025): https://pubmed.ncbi.nlm.nih.gov/40388765/
• Best practices in managing checkpoint-inhibitor-induced thyroid dysfunction (2025): https://pubmed.ncbi.nlm.nih.gov/39792969/

If you were started on levothyroxine because of immunotherapy-related thyroiditis rather than ordinary primary hypothyroidism, the delayed-risk framework in this article still applies in principle, but the timelines and monitoring cadence used by your oncology and endocrinology team may differ from the general guidance below, and that team's plan should take precedence.

Hair shedding, mood changes, and glucose effects: what has support and what doesn't

Telogen effluvium, a wave of hair shedding roughly two to four months after a meaningful dose change in either direction, is a recognized, though under-recognized, delayed effect tied to the hair follicle's response to shifting thyroid hormone levels. It is usually self-limited once TSH restabilizes; hair loss persisting well beyond that window deserves evaluation for other causes, such as iron deficiency, rather than being assumed to be the drug.

A delayed mood effect from prolonged over-replacement is biologically plausible, since chronic mild hyperthyroidism affects the HPA axis, and some observational data have reported worse anxiety and depression scores in people with a persistently suppressed TSH. This is observational, not trial-confirmed, evidence, and it does not establish that levothyroxine causes a depressive disorder independent of thyroid status.

A link between over-replacement and modestly worse glucose control has also been proposed, based on thyroid hormone's known role in hepatic glucose output and insulin sensitivity, and some retrospective cohort data have supported it. Anyone managing both diabetes and thyroid disease should expect that a levothyroxine dose change can shift glucose control and should plan a glucose or HbA1c recheck after a significant dose adjustment, even though the exact magnitude reported in any one study needs verification before being treated as a fixed number.

Drug interactions that create delayed dosing problems

Several common medications reduce levothyroxine absorption enough to functionally under-dose a patient for weeks before it shows up on labs, and the reverse problem, over-treatment, appears later if the interacting drug is stopped without adjusting the levothyroxine dose back down.

This table reflects widely taught pharmacology principles for levothyroxine interactions; exact absorption-reduction percentages vary by study and formulation and should be confirmed against a current pharmacology reference rather than treated as fixed figures.

A decision guide for delayed symptoms on long-term levothyroxine

Most people on stable levothyroxine therapy are not seen by a clinician between annual or semiannual labs, which is exactly the gap where delayed effects go unnoticed. This framework is meant to help decide what a given symptom, timed against your last dose change or lab check, should trigger, it does not replace an individualized plan from your prescriber.

Step 1: How long since your last dose change or lab check?

• Under 4 weeks: most new symptoms (jitteriness, mild insomnia) reflect the body still equilibrating to the new dose. Note them; a repeat TSH before 4 to 6 weeks generally will not be interpretable yet.
• 4 weeks to 6 months: this is the window where absorption interactions (new PPI, new calcium or iron supplement, new estrogen) most often distort TSH. If you started or stopped one of these, mention it before assuming the levothyroxine dose itself is wrong.
• Beyond 6 months to years on an unchanged dose: this is the window for slow-building effects, bone and cardiac risk from an undetected TSH drift, particularly if you have not had labs checked in over a year.

Step 2: What is the symptom category, and does it change urgency?

• Chest symptoms, irregular or racing heartbeat, new shortness of breath on exertion, palpitations, warrant prompt evaluation regardless of timing, since these can reflect atrial fibrillation and should not wait for a routine visit.
• Possible adrenal warning signs, new severe fatigue, low blood pressure, nausea, or fainting appearing within about 2 months of starting or increasing levothyroxine, are an urgent-care-level concern, not a "wait for the next visit" issue, because untreated adrenal crisis can be life-threatening.
• Bone-related symptoms, a fracture from minor trauma, or new unexplained bone pain, in someone on a suppressive or long-term high dose, should prompt a bone density discussion, not just a TSH check.
• Hair shedding, mild mood changes, or mild GI symptoms are lower urgency and reasonable to bring up at the next scheduled visit unless they are severe or rapidly worsening.

Step 3: Who should not wait for the next annual check regardless of symptoms

• Postmenopausal women on a suppressive dose for thyroid cancer
• Anyone over 65, since age-related changes in T4 clearance make dose drift more likely and less obviously symptomatic
• Anyone with known heart disease or a prior arrhythmia
• Anyone recently started on, or recently stopped, an interacting medication from the table above
• Anyone pregnant, where TSH targets and check intervals are set separately by the treating clinician

Step 4: When self-monitoring is not enough Symptom-watching alone cannot substitute for periodic TSH testing, because the two most consequential delayed effects, bone loss and atrial fibrillation, are frequently silent until they are advanced. A structured, guideline-based recheck interval, individualized by your prescriber based on your age, dose stability, and risk factors, is the actual safeguard; this framework is only meant to help decide what to do with a symptom in between those checks.

What is established, what is plausible, and what remains uncertain

Established: chronic TSH suppression from levothyroxine over-replacement increases fracture risk and atrial fibrillation risk, and correctly matched dosing with regular monitoring reduces both. Starting thyroid hormone in a patient with untreated adrenal insufficiency can precipitate adrenal crisis, and this is reflected in standard prescribing information.

Plausible but not firmly quantified on this page: the exact percentage increases in fracture risk, AF risk, coronary mortality, or fasting glucose reported in specific published studies. The direction of these associations is well supported in the literature; the precise numbers vary across studies and should be verified against the primary paper before being used in a clinical or patient-facing context.

Not established: that levothyroxine at a correctly matched dose causes any of these delayed effects independent of TSH drift, or that levothyroxine directly causes weight gain, depression, or hair loss when TSH remains in range. Treating subclinical hypothyroidism in older adults, where the TSH is only mildly elevated, has been studied in randomized trial data and has generally not shown symptom or quality-of-life benefit, a reason some clinicians are cautious about starting therapy in that group in the first place.

When to seek care rather than wait

• New or worsening irregular heartbeat, palpitations, or shortness of breath, treat as urgent, not something to raise at a future appointment
• Severe fatigue, low blood pressure, or persistent nausea appearing within about two months of starting or increasing levothyroxine, seek prompt evaluation for possible adrenal insufficiency
• A fracture from minor trauma while on long-term or suppressive therapy, needs bone density evaluation
• Any symptom you are unsure about, especially if it is new and you have not had labs checked recently

Evidence limits of this page

This article draws on general endocrine pharmacology, widely cited cohort and trial literature on subclinical thyroid dysfunction, standard FDA prescribing warnings, and two recent papers on a distinct and emerging population (checkpoint-inhibitor-associated thyroid dysfunction). Several precise effect-size figures that circulate in secondary sources about levothyroxine's delayed risks could not be verified against a specific, checked primary citation for this draft and have been described qualitatively instead. Anyone citing a specific number from this topic in a clinical or publication context should locate and confirm the original study rather than relying on a secondary summary.